Top
image credit: Pixabay

Cancer patients receiving common heart drugs have less heart damage from cancer therapy

December 4, 2019

Cancer patients receiving common heart drugs have less heart damage from cancer therapy, according to research presented today at EuroEcho 2019, a scientific congress of the European Society of Cardiology (ESC). For every ten patients with breast or hematological cancer treated with heart drugs, one case of cardiotoxicity could be avoided.

“Our study provides support for the routine use of beta-blockers, angiotensin converting enzyme (ACE) inhibitors, or angiotensin II receptor blockers (ARBs) in patients receiving cancer treatment but the decision should be made on a case by case basis,” said study author Dr Sergio Moral, of Hospital Universitari Josep Trueta and Hospital Santa Caterina, Girona, Spain.

Read More on The Medical News